首页> 外文期刊>Journal of Clinical Oncology >Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: A prospective trial of the Sarah cannon research institute
【24h】

Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: A prospective trial of the Sarah cannon research institute

机译:分子基因表达谱分析可预测原发部位未知的癌症患者的起源组织和直接部位特异性治疗:萨拉·加农炮研究所的一项前瞻性试验

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: Molecular tumor profiling is a promising diagnostic technique to determine the tissue of origin in patients with carcinoma of unknown primary site (CUP). However, the clinical value of these molecular predictions is unknown. We used tumor profiling results to direct site-specific therapy for patients with CUP. Patients and Methods: Tumor biopsy specimens from previously untreated patients with CUP were tested with a 92-gene reverse transcriptase polymerase chain reaction cancer classification assay. When a tissue of origin was predicted, patients who were treatment candidates received standard site-specific first-line therapy. Results: Of 289 patients enrolled, 252 had successful assays performed, and 247 (98%) had a tissue of origin predicted. Sites most commonly predicted were biliary tract (18%), urothelium (11%), colorectal (10%), and non-small-cell lung (7%). Two hundred twenty-three patients were treatment candidates, and 194 patients received assay-directed site-specific treatment. In these 194 patients, the median survival time was 12.5 months (95% CI, 9.1 to 15.4 months). When the assay predicted tumor types that were clinically more responsive, the median survival was significantly improved when compared with predictions of more resistant tumors (13.4 v 7.6 months, respectively; P = .04). Conclusion: In this large prospective trial, molecular tumor profiling predicted a tissue of origin in most patients with CUP. The median survival time of 12.5 months for patients who received assay-directed site-specific therapy compares favorably with previous results using empiric CUP regimens. Patients with CUP predicted to have more responsive tumor types had longer survival compared with patients with less responsive tumor types. Molecular tumor profiling contributes to the management of patients with CUP and should be a part of their standard evaluation.
机译:目的:分子肿瘤特征分析是一种可用于确定原发部位未知癌(CUP)患者的来源组织的有前途的诊断技术。但是,这些分子预测的临床价值尚不清楚。我们使用肿瘤分析结果指导针对CUP患者的特定部位治疗。患者和方法:使用92基因逆转录酶聚合酶链反应癌症分类分析法对先前未经治疗的CUP患者的肿瘤活检标本进行了测试。当预测到起源组织时,作为候选治疗对象的患者将接受标准的部位特异性一线治疗。结果:在289名患者中,有252名成功进行了化验,其中247名(98%)预测了原发组织。最常被预测的部位是胆道(18%),尿路上皮(11%),结直肠(10%)和非小细胞肺(7%)。 233位患者为治疗候选者,其中194位患者接受了针对测定的针对部位的治疗。在这194名患者中,中位生存时间为12.5个月(95%CI,9.1至15.4个月)。当该测定法预测出临床上具有更高反应性的肿瘤类型时,与更具抵抗力的肿瘤的预测值相比,中位生存期显着提高(分别为13.4 v 7.6个月; P = .04)。结论:在这项大型前瞻性试验中,分子肿瘤特征分析预测了大多数CUP患者的起源组织。接受化验指导的部位特异性治疗的患者的中位生存时间为12.5个月,与以往使用经验性CUP方案的结果相比具有优势。与具有较少反应性肿瘤类型的患者相比,预测具有更多反应性肿瘤类型的CUP患者具有更长的生存期。分子肿瘤概况分析有助于CUP患者的治疗,应成为他们标准评估的一部分。

著录项

  • 来源
    《Journal of Clinical Oncology》 |2013年第2期|共7页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号